Answers are grounded in this paper and cite their sources.
Background Effective and cost-effective treatments are not always optimally implemented. The benefit forgone due to sub-optimal implementation is often not considered or estimated. We use the economic concept of “incremental net monetary benefit” (INMB) to demonstrate how this can be valued. This approach can inform decision-making when used to estimate the value for money of potential future quality improvement (QI) programmes. We illustrate these analyses using the case of antenatal magnesium sulphate (MgSO 4 ), a cost-effective treatment for the prevention of cerebral palsy in preterm births. We estimate the optimal implementation of MgSO 4 , the INMB lost due to sub-optimal implementation, and the value of future implementation initiatives to increase the use of MgSO 4 . Methods We estimated MgSO 4 treatment implementation for babies under 32 weeks' gestation using routine data on its uptake between 2014 and 2022 in England, Scotland, and Wales. The optimal uptake level of MgSO 4 was estimated using clinical judgment. The societal lifetime INMB of MgSO 4 for the prevention of cerebral palsy in preterm births was obtained from the literature. The INMB of sub-optimal implementation over time was estimated as the difference between optimal and actual uptake over time in each country. We estimated the cost-effectiveness of a hypothetical future QI programme based on different scenarios of implementation effectiveness and costs. Results The optimal uptake of MgSO 4 was 95%. The INMB forgone associated with sub-optimal MgSO 4 uptake has reduced over time, as uptake has increased. However, in 2022, the societal lifetime INMB forgone was still £18.2 m in England, £3.7 m in Scotland, and £1.0 m in Wales. A future QI programme across all three countries achieving a 5% increase in MgSO 4 uptake over one year, and costing £987,500 to implement, would be cost-effective; generating £7.5 m in INMB. Future implementation initiatives are likely to be cost-effective within a range of different implementation effectiveness and costs. Conclusions The case of MgSO 4 treatment for preterm birth illustrates how sub-optimal implementation of evidence-based interventions can be associated with high opportunity costs measured as INMB forgone. This approach provides valuable quantification of the value for money of future QI programmes to improve the implementation of these interventions.
No takes yet. Share an insight, caveat, or question.
Sillero‐Rejon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: